243 related articles for article (PubMed ID: 34085795)
21. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
Xi Y; Liu G; Liu D; Jiang J; Gong R
Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
[TBL] [Abstract][Full Text] [Related]
22. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Shao F; Li Y; Zhao Y
Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
24. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
26. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.
Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L
Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095
[TBL] [Abstract][Full Text] [Related]
27. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.
Wei J; Zhang W; Feng L; Gao W
Medicine (Baltimore); 2017 Sep; 96(37):e8034. PubMed ID: 28906392
[TBL] [Abstract][Full Text] [Related]
28. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
29. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
30. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
31. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
[TBL] [Abstract][Full Text] [Related]
32. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients.
Yang B; Xie L; Zhang H; Zhu Q; Du Y; Luo X; Chen X
J Gynecol Oncol; 2018 May; 29(3):e35. PubMed ID: 29533020
[TBL] [Abstract][Full Text] [Related]
33. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
Park JY; Lee SH; Seong SJ; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Gynecol Oncol; 2013 Apr; 129(1):7-11. PubMed ID: 23283299
[TBL] [Abstract][Full Text] [Related]
34. Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort.
Li X; Wang Y; Wang J; Fan Y; Wang J
J Transl Med; 2024 Feb; 22(1):127. PubMed ID: 38308352
[TBL] [Abstract][Full Text] [Related]
35. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Ga H; Taguchi A; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Osuga Y
Arch Gynecol Obstet; 2023 Nov; 308(5):1629-1634. PubMed ID: 37310452
[TBL] [Abstract][Full Text] [Related]
37. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics and fertility preserving treatment of atypical polypoid adenomyoma.
Wang Q; Shan W; Yang B; Xue Y; Lou Y; Chen X
Front Oncol; 2024; 14():1386931. PubMed ID: 38863630
[TBL] [Abstract][Full Text] [Related]
40. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
